Formulated for stroke prevention and DVT to manage blood clotting and support cardiovascular safety.
Mechanism of Action
Rivaroxaban is a highly selective inhibitor of Factor Xa. By blocking this key enzyme in the coagulation cascade, it prevents thrombin generation and blood clot formation without requiring constant monitoring like warfarin.
Route of Administration
Oral
Onset Time
2–4 hours
Duration
24 hours
Contraindications
Active pathological bleeding, Severe renal impairment, Moderate to severe hepatic impairment, Pregnancy
Severe Adverse Events
Major hemorrhage, Spinal hematoma, Anaphylaxis — requires immediate medical attention
Information related to Xarelto is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
